Advertisement

Osteoporosis International

, Volume 29, Issue 7, pp 1665–1670 | Cite as

Pitfalls in bone density monitoring in prostate cancer during anti-resorptive treatment

  • Y.-M. Cheung
  • S. k. Ramchand
  • M. Grossmann
Case Report
  • 84 Downloads

Abstract

A 74-year-old man presented to the Andrology Clinic for management of potential complications of androgen deprivation therapy for prostate cancer. He had a rising prostate-specific antigen with a concurrent rise in alkaline phosphatase and bone remodeling markers. This was despite treatment with a radical prostatectomy, androgen deprivation, and anti-resorptive therapy. A follow-up dual-energy X-ray absorptiometry scan revealed a marked increase in his bone mineral density at both the lumbar spine and femoral neck. This increase, especially in the context of rising bone remodeling markers, was unlikely due to the effect of anti-resorptive therapy alone. Subsequent whole-body bone scintigraphy demonstrated a “superscan” phenomenon which is characterized by uniform and avid tracer retention throughout the skeleton, in this case due to widespread skeletal metastasis, so that the usual physiological uptake in the kidneys is no longer observed and can be misinterpreted as a “normal” scan if the absence of the kidneys is not recognized. This case highlights the importance of considering diffuse metastatic disease when there is a rapid increase in bone mineral density, even in individuals treated with anti-resorptive therapy.

Keywords

Androgen deprivation therapy Anti-resorptive therapy Bone mineral density Prostate cancer Superscan 

Notes

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Smith MREB, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745–755CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA oncology 3(4):524–548CrossRefGoogle Scholar
  3. 3.
    Grossmann M, Zajac JD (2011) Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin N Am 40(3):655–671CrossRefGoogle Scholar
  4. 4.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164CrossRefPubMedGoogle Scholar
  5. 5.
    Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745–755CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL, Holen I (2014) Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research 20(11):2922–2932CrossRefGoogle Scholar
  8. 8.
    Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL, Holen I (2014) Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer 21(5):769–781CrossRefPubMedGoogle Scholar
  9. 9.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468CrossRefPubMedGoogle Scholar
  10. 10.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879–882CrossRefPubMedGoogle Scholar
  11. 11.
    Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813–822CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Morteímans L, Reske SN (2003) Bone scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30(12):BP99–B106PubMedGoogle Scholar
  13. 13.
    Genant HK, Bautovich GJ, Singh M, Lathrop KA, Harper PV (1974) Bone-seeking radionuclides: an in vivo study of factors affecting skeletal uptake. Radiology 113(2):373–382CrossRefPubMedGoogle Scholar
  14. 14.
    Galasko CS (1975) The pathological basis for skeletal scintigraphy. J Bone Joint Surg British 57(3):353–359CrossRefGoogle Scholar
  15. 15.
    Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ (2003) Radionuclide bone imaging: an illustrative review. Radiographics 23(2):341–358CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  1. 1.Department of EndocrinologyAustin HealthMelbourneAustralia
  2. 2.Department of MedicineThe University of Melbourne - Austin HeathMelbourneAustralia

Personalised recommendations